Sørensen M G, Henriksen K, Schaller S, Karsdal M A
Pharmos Bioscience A/S, Herlev Hovedgade, Herlev, Denmark.
Biomarkers. 2007 May-Jun;12(3):266-86. doi: 10.1080/13547500601070842.
Although several treatments for osteoporosis exist, further understanding of the mode of action of current treatments, as well as development of novel treatments, are of interest. Thus, preclinical models of osteoporosis are very useful, as they provide the possibility for gaining knowledge about the cellular mechanisms underlying the disease and for studying pharmaceutical prevention or intervention of the disease in simple and strictly controlled systems. In this review, we present a comprehensive collection of studies using biochemical markers of bone turnover for investigation of preclinical models of osteoporosis. These range from pure and simple in vitro systems, such as osteoclast cultures, to ex vivo models, such as cultures of embryonic murine tibiae and, finally, to in vivo models, such as ovariectomy and orchidectomy of rats. We discuss the relevance of the markers in the individual models, and compare their responses to those observed using 'golden standard' methods.
尽管针对骨质疏松症已有多种治疗方法，但进一步了解现有治疗方法的作用模式以及开发新的治疗方法仍备受关注。因此，骨质疏松症的临床前模型非常有用，因为它们为了解该疾病潜在的细胞机制以及在简单且严格可控的系统中研究该疾病的药物预防或干预提供了可能。在本综述中，我们全面收集了一系列使用骨转换生化标志物来研究骨质疏松症临床前模型的研究。这些模型范围从简单纯粹的体外系统，如破骨细胞培养，到离体模型，如胚胎小鼠胫骨培养，最后到体内模型，如大鼠卵巢切除术和睾丸切除术。我们讨论了这些标志物在各个模型中的相关性，并将它们的反应与使用“金标准”方法所观察到的反应进行比较。
